How IZERVAY works

IZERVAY directly targets the source of retinal cell death and loss of photoreceptors.1
By inhibiting C5, IZERVAY aims to reduce inflammation, retinal cell death,
and loss of photoreceptors associated with the development and progression of GA.14-16
IZERVAY is a pegylated RNA aptamer molecule designed to target C5. Inhibiting C5 preserves upstream benefits of C3 and may prevent the formation of the membrane attack complex (MAC), which initiates retinal cell death.1,14

IZERVAY comes in comprehensive packaging for seamless administration1

  • Single-Use Vial
  • Sterile 5-micron filter needle 19-gauge x 1½ inch
  • Sterile 1 mL Luer lock syringe with a 0.1 mL dose mark
izervay avacincapted pegol intravitreal solution 2 mg comprehensive packaging

Preparation and Administration

vial

Unopened vials of IZERVAY can remain outside the refrigerator for 24 hours1

injection

IZERVAY is a 2 mg intravitreal injection administered once monthly1
(~28 ± 7 days) for up to 12 months

Download our Administration Brochure

Sign up for updates

Sign Up

See GA, start IZERVAY

Next Page
IZERVAY™ IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
Warnings and Precautions
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure
    • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
Adverse Reactions
  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.